Torasemide versus furosemide in patients with congestive heart failure: a double-masked, randomized study

Ferrara, Nicola; Leosco, Dario; Prete, Mario Del; Lombardi, Luigi; Landino, P.; Abete, Pasquale; Longobardi, Giancarlo; Rengo, Franco

doi:10.1016/s0011-393x(97)80026-4

Cited by 9 publications

(11 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In summary, CHF did not affect the rate or completeness of absorption of torsemide after oral administration, whereas delayed absorption and lowered bioavailability of furosemide was observed [1]. Ferrara et al (1997) In this study, 40 cardiopathic patients (27 men and 13 women, mean age: 62.9 years) with CHF (NYHA functional class II and III) of stable clinical condition and absence of diuretic therapy during the week preceding the study were randomized to a double-masked trial (20 patients were administered torsemide 10 mg and 20 patients were given furosemide 25 mg) q.d. for 28 days [29].…”

Section: Goebel (1993)mentioning

confidence: 87%

“…In fact, torsemide but not furosemide was shown to inhibit the transcardiac extraction of aldosterone in patients with CHF [23]. The antialdosterone effects of torsemide also give it a potassium-sparing effect, an effect that is not seen with furosemide [24][25][26]. Furthermore, torsemide has been shown to inhibit angiotensin II-stimulated vascular smooth muscle cell growth, whereas furosemide has not [20,21].…”

Section: Mineralcorticoid Receptor Antagonismmentioning

confidence: 99%

“…The vasodilating and blood pressure-lowering actions of torsemide may also help to lower afterload compared with furosemide, which is a common and perpetuating problem in CHF. In fact, randomized trials have shown significantly greater reductions in blood pressure and afterload (left ventricular systolic volume) and greater improvements in ejection fraction (EF) with torsemide compared with furosemide [27][28][29][30].…”

Section: Vasodilatory Effectsmentioning

confidence: 99%

“…Torsemide has potassium sparing effects and significantly lowers blood pressure and improves EF, whereas furosemide does not [29] Yamato et al…”

mentioning

confidence: 99%

See 3 more Smart Citations

Should Torsemide Be the Loop Diuretic of Choice in Systolic Heart failure?

DiNicolantonio

2012

Future Cardiol.

View full text Add to dashboard Cite

Furosemide is the most widely prescribed loop diuretic in the setting of systolic heart failure (HF), yet torsemide has been shown to have less inter- and intra-individual variation in bioavailability and a longer duration of action compared with furosemide. Thus, a systematic review and meta-analysis of randomized controlled trials comparing torsemide versus furosemide in patients with systolic HF using OVID MEDLINE, Excerpta Medica (Embase), Web of Science, PubMed and Google Scholar was performed. Extracted data included study design, sample characteristics, intervention, outcomes and control for potential confounding factors. A DerSimonian and Laird random-effects model was used to compute summary risk ratios for HF and cardiovascular (CV) readmission outcomes. Two randomized trials comparing furosemide with torsemide in 471 patients with systolic HF were identified. Compared to furosemide, torsemide significantly reduced total HF readmissions (relative risk [RR]: 0.41, 95% CI: 0.28-0.61, p < 0.0001) and HF readmissions (RR: 0.53, 95% CI: 0.33-0.84, p = 0.008) as well as CV readmissions (RR: 0.77, 95% CI: 0.60-0.98, p = 0.03) in patients with "at least 1 readmission." Moreover, compared with furosemide, torsemide caused a 14% reduction in all-cause mortality (RR: 0.86 [0.53-1.39], p = 0.54). Compared with furosemide, torsemide significantly reduces HF and CV-related hospital readmissions in systolic HF. Furthermore, torsemide is associated with a trend in reducing all-cause mortality.

show abstract

Section: Goebel (1993)mentioning

confidence: 87%

Section: Mineralcorticoid Receptor Antagonismmentioning

confidence: 99%

Section: Vasodilatory Effectsmentioning

confidence: 99%

“…Torsemide has potassium sparing effects and significantly lowers blood pressure and improves EF, whereas furosemide does not [29] Yamato et al…”

mentioning

confidence: 99%

See 2 more Smart Citations

Should Torsemide Be the Loop Diuretic of Choice in Systolic Heart failure?

DiNicolantonio

2012

Future Cardiol.

View full text Add to dashboard Cite

show abstract

“…8,11 Compared with other loop diuretics, torsemide intrinsically blocks sympathetic nervous system and aldosterone activity, which may lead to favorable cardiac remodeling and decreased kaliuresis. [12][13][14][15] In an open-label, randomized controlled trial, patients treated with torsemide were found to have decreased myocardial fibrosis on 8-month endomyocardial biopsy specimens. 16 Although intriguing, only a few clinical outcome studies have subsequently compared torsemide with other loop diuretics.…”

Section: Diuretic Therapymentioning

confidence: 99%

Volume Overload in Heart Failure

Houston

Kalathiya

Kim

et al. 2015

Mayo Clinic Proceedings

View full text Add to dashboard Cite

Acute decompensated heart failure is the leading cause of hospital admission in the United States, with a high risk of readmission within 30 days. Most acute decompensated heart failure admissions are driven by congestive signs and symptoms resulting from fluid and sodium overload. We reviewed the evidence base addressing the management and prevention of fluid overload in heart failure, focusing on recent clinical trials. All the references in this review were obtained through PubMed and had at least 1 of the following key words: heart failure and volume overload, congestion, loop diuretics, thiazide diuretics, aldosterone antagonists, dopamine, cardiorenal syndrome, nesiritide, vasopressin antagonists, ultrafiltration, sodium restriction, fluid restriction, telemonitoring, and invasive hemodynamic monitoring. We also reviewed relevant references cited in the obtained articles, especially articles addressing methods of treating or preventing volume overload in patients with heart failure.

show abstract